Oral Pharmaceutical Composition with Plant Alkaloid for Dependency Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing solid pharmaceutical forms of cholinergic agents, such as alkaloids, face challenges with uniform distribution and segregation of active substances, leading to inconsistent bioavailability and potential overdose risks.
Innovation Solution
An oral pharmaceutical composition is developed containing a cholinergic agent like cytisine, galantamine, lobeline, or anabasine, combined with excipients such as cellulose powder, calcium sulphate, silica colloidal, and magnesium stearate, ensuring uniform distribution and high bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cholinergic agents like alkaloids are used in solid pharmaceutical forms, then therapeutic effect is achieved, but uniform distribution of active substance is poor leading to segregation
Solution Approach 1:
The patent introduces a water-soluble polymer as an intermediary carrier that forms a stable complex with the cholinergic agent. This polymer intermediary ensures uniform distribution of the active substance throughout the solid dosage form while maintaining its therapeutic activity, preventing segregation issues that occur with conventional excipient combinations.
Solution Approach 2:
The invention creates a composite pharmaceutical formulation combining cholinergic agents with specific water-soluble polymers and excipients in defined ratios. This composite structure ensures homogeneous distribution of the active substance, improves disintegration characteristics, and maintains therapeutic efficacy without the segregation problems of traditional solid forms.
2Reliability
If higher doses of alkaloids are used to ensure therapeutic effect, then treatment efficacy improves, but toxicity increases
Solution Approach 1:
The patent optimizes the concentration parameters of cholinergic agents within a specific range (0.1-50% by weight, preferably 2-15%) and combines them with water-soluble polymers in 1:1 proportion. This parameter optimization achieves effective therapeutic levels while maintaining safety margins, avoiding the toxicity associated with higher doses of pure alkaloids.
3Ease of manufacture
If conventional excipients are used in solid forms, then manufacturing is simpler, but uniformity of active substance content and dissolution are insufficient
Solution Approach 1:
The water-soluble polymer serves as an intermediary that facilitates uniform distribution of cholinergic agents during manufacturing. The polymer's solubility and binding properties ensure homogeneous mixing and consistent active substance content throughout the dosage form, achieving manufacturing precision without excessive complexity.
Solution Approach 2:
The patent specifies precise parameter ranges for excipient composition (water-soluble polymer in 1:1 proportion with alkaloid, total cellulose powder and calcium sulphate from 64.5-97.5%) that optimize both manufacturability and uniformity of active substance distribution, achieving precision through controlled parameter selection rather than complex processes.
4Stability of the object's composition
If solid dosage forms are used for alkaloids, then storage stability improves, but disintegration and bioavailability are reduced
Solution Approach 1:
The patent develops a composite solid dosage form combining cholinergic agents with water-soluble polymers and specific excipients that maintains storage stability while ensuring rapid disintegration. The composite structure allows the solid form to remain stable during storage yet disintegrate effectively in the gastrointestinal tract, improving bioavailability compared to conventional solid forms.
Solution Approach 2:
The patent optimizes disintegration parameters by controlling the ratio of water-soluble polymer to alkaloid (1:1) and selecting specific excipient combinations with controlled solubility and disintegration characteristics. These parameter changes enable the solid form to maintain stability during storage while achieving rapid disintegration and high bioavailability upon administration.
Data Source
AI summary
Provided herein is an oral pharmaceutical composition that contains a cholinergic agent, a natural plant alkaloid in particular, selected from the group of lobeline, anabasine, cytisine, galantamine or acceptable salts thereof, in the form of tablets and capsules. The oral pharmaceutical composition is applicable in the treatment of dependency and addiction to nicotine, tobacco products, and alcohol.